0203 GMT - A high-severity influenza season in the U.S. could benefit vaccine makers including Australia's CSL, Morgan Stanley analyst David L. Bailey says. He points out that the U.S. CDC has designated its first high-severity season since 2017-18, with hospitalization rates at the end of February sitting at their highest levels since 2010-11. Bailey doesn't speculate on the degree to which vaccine demand could rise or the extent to which CSL and others could benefit. However, he thinks that vaccination rates may rise. CSL's fiscal first-half influenza vaccine sales fell 15% amid lower U.S. vaccination rates for people aged 15-64, he adds. Morgan Stanley has an overweight rating and A$313.00 target price on the stock, which is down 0.8% at A$253.20. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
March 20, 2025 22:03 ET (02:03 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。